3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
9
Phase NA
5
Phase 2
4
Phase 2/3
2
Status
Recruiting
2
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Other hematologic neoplasm
23
Lymphoid
8
Myeloid
6
CNS
5
Plasma cell
4
Gastrointestinal
4
Thoracic
3
Head & Neck
3
Gynecologic
3
Dermatologic
3
Genitourinary
2
Endocrine
2
Sarcoma
1
Conditions
Prostatic Neoplasms
76
Urinary Bladder Neoplasms
20
Neoplasms
11
Carcinoma, Transitional Cell
8
Non-Muscle Invasive Bladder Neoplasms
6
Lung Neoplasms
6
Carcinoma, Renal Cell
6
Neoplasm Metastasis
5
Breast Neoplasms
4
Testicular Neoplasms
3
Recurrence
3
Prostatic Neoplasms, Castration-Resistant
3
Pancreatic Neoplasms
3
Ovarian Neoplasms
3
Kidney Neoplasms
3
Colorectal Neoplasms
3
Carcinoma in Situ
3
Adenocarcinoma
3
Acute Kidney Injury
3
Uterine Cervical Neoplasms
2
Prostate CA
2
Melanoma
2
Liver Neoplasms
2
Kidney Failure, Chronic
2
Hematologic Neoplasms
2
Head and Neck Neoplasms
2
Gallbladder Neoplasms
2
Critical Illness
2
Colonic Neoplasms
2
Agnosia
2
Interventions
pertuzumab
1
alectinib
1
Trastuzumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 2/3
×
Hematologic Neoplasms
×
Genitourinary
×
Clear all
NCT05786716
2025-12-02
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled
NCT05770037
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled